A5002645924- Vibrio bacteria research studies
- Bacterial Infections and Vaccines
- Pneumonia and Respiratory Infections
- SARS-CoV-2 and COVID-19 Research
- Respiratory viral infections research
- Salmonella and Campylobacter epidemiology
- Influenza Virus Research Studies
- Escherichia coli research studies
- Viral gastroenteritis research and epidemiology
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immune Response and Inflammation
- Diphtheria, Corynebacterium, and Tetanus
- Antibiotic Resistance in Bacteria
- Child Nutrition and Water Access
- Gastrointestinal Bleeding Diagnosis and Treatment
- Inhalation and Respiratory Drug Delivery
- Hepatitis B Virus Studies
- Mycobacterium research and diagnosis
EuBiologics (South Korea)
2014-2024
Korea University
2014-2015
In October, 2017, WHO launched a strategy to eliminate cholera by 2030. A primary challenge in meeting this goal is the limited global supply capacity of oral vaccine and worsening outbreaks since 2021. To help address current shortage vaccine, prequalified Euvichol-Plus was reformulated reducing number components inactivation methods. We aimed evaluate immunogenicity safety Euvichol-S (EuBiologics, Seoul, South Korea) compared with an active control Shanchol (Sanofi Healthcare India,...
Abstract Background Numerous vaccine strategies are being advanced to control SARS-CoV-2, the cause of COVID-19 pandemic. EuCorVac-19 (ECV19) is a recombinant protein nanoparticle that displays SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes. Methods Initial study phase 2 randomized, observer-blind, placebo-controlled trial assess immunogenicity, safety, and tolerance ECV19 was carried out between July October 2021. Two hundred twenty-nine participants were enrolled at...
EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective this study was to determine the longer-term antibody response vaccine.To assess immunogenicity 6 and 12 months vaccination, participants in (NCT04783311) were excluded if they: 1) withdrew, 2) infection or additional 3) exhibited increasing...
Abstract EuCorVac‐19 (ECV‐19) is a recombinant receptor binding domain (RBD) COVID‐19 vaccine that displays the RBD (derived from SARS‐CoV‐2 Wuhan strain) on immunogenic liposomes. This study compares safety and immunogenicity of ECV‐19 to COVISHIELD TM (CS) adenoviral‐vectored vaccine. Interim analysis presented randomized, observer‐blind, immunobridging Phase 3 trial in Philippines 2600 subjects, with treatment biospecimen collection between October 2022 January 2023. Healthy male female...
Safety and Immunogenicity Assessment of an Oral Cholera Vaccine through Phase I Clinical Trial in KoreaThe safety, tolerability immunogenicity oral cholera vaccine (OCV) was assessed adult Korean male open-label, non-comparative clinical study.Two doses with interval 2 weeks were given to 20 healthy subjects.A total 7 adverse events occurred 6 subjects.However, no clinically significant change observed electrocardiograms, vital signs, physical examinations, laboratory tests.The OCV evaluated...
Streptococcus pneumoniae is the causative agent of many diseases, most notably pneumonia. Vaccine development using pneumococcal capsular polysaccharides (CPS) a current focus, but purifying CPS sufficient quality has been challenging. A purification process for comprising conventional methods such as ultrafiltration, CTAB precipitation, and chromatography was previously established; however, this method resulted in high cell wall polysaccharide (CWPS) contamination, especially serotype 5....
Considering the cholera menace in India and to seek licensure of oral vaccine (OCV), Euvichol-Plus, we conducted a clinical trial compare immunogenicity safety Euvichol-Plus with Shanchol healthy Indian adults children. This phase 3, open-label, multicentre, randomised, non-inferiority, parallel-group, comparative study was at seven sites across involving 416 (aged ≥18–60 years) children ≥1 <18 years). Healthy individuals who agreed participate through voluntary written informed consent form...
Glycoconjugate vaccines are in which a bacterial polysaccharide antigen is conjugated to carrier protein enhance immunogenicity by promoting T cell-dependent immune response. However, the free (unreacted) polysaccharides remaining after conjugation process can inhibit of conjugate vaccine. Thus, we aimed reduce unbound polysaccharide-protein for development new 15-valent pneumococcal vaccine (PCV15) varying some factors that may affect results such as polysaccharide/protein ratio, size, and...
Background: To help address the current shortage of vaccine, a WHO prequalified bivalent whole cell (WC) OCV, Euvichol-Plus was reformulated by reducing number components and inactivation methods. Methods: The phase 3, observer-blind, randomized, active-controlled trial performed in healthy participants aged 1-40 years Nepal.Eligible were enrolled to receive two doses either Euvichol-S (Euvichol-Simplified, process-optimized monovalent WC OCV containing components) or an active control...
Pneumococcal conjugate vaccines (PCVs) have been effective in reducing the disease burden caused by Streptococcus pneumoniae. The first licensed PCV (PCV7) was composed of capsular polysaccharides from seven serotypes. This followed PCV10, then PCV13, and currently there are a number higher valency development. As part licensure, new vaccine iterations require assessment immunogenicity. Since some antibodies can be non-functional, measuring functional is desirable. To meet this need,...
The typhoid conjugate vaccine (TCV) ensures a long-lasting protective immune response, requires fewer doses, and is fit for children under 2 years of age. From Phase I, EuTCV displayed considerable immunogenicity reliable safety, thus endorsing further examination in II/III trials. Therefore, clinical study (NCT04830371) was performed to evaluate its efficacy healthy Filipino participants aged 6 months 45 who received the test (Arm A, B, C) or comparator Typbar-TCV® D). Sera samples were...